Evaluation of biomarkers of survival response in hormone-refractory prostate cancer patients treated with suramin

Rajeshwari Sridhara, Mario A. Eisenberger, Victoria J. Sinibaldi, Leonard M. Reyno, Merrill J. Egorin

Research output: Contribution to journalArticlepeer-review

Abstract

Hormone-refractory prostate cancer (HRPC) patients often have nonmeasurable disease. In such patients, predictive biomarkers other than tumor response may be required to compare therapeutic effects. We examined the predictive value for survival of various clinical and laboratory parameters, including prostate-specific antigen (PSA), in HRPC patients treated with suramin. Data from 103 HRPC patients were analyzed using various survival analyses, the likelihood ratio approach, and logistic regression analyses. When pretreatment factors, percentage decrease in PSA at 4 weeks from start of treatment (ΔPSA), and updated survival data were fit by a multivariate Cox proportional hazards model, acid phosphatase, lactate dehydrogenase, and ΔPSA were significant, with risk ratios close to 1. There was a decrease in likelihood ratio with increasing ΔPSA. A logistic regression model was developed to predict the probability of < 1 year of survival from the start of treatment. Hemoglobin and ΔPSA were found to be significant variables. However, in view of the complexities involving the relationship between PSA expression and prostate cancer growth and possible selective effect of treatment on PSA, further prospective testing is necessary. Therefore, ΔPSA cannot necessarily be used as a biomarker for survival response in individual patients during the evaluation of the therapeutic response of HRPC to new antineoplastic drugs.

Original languageEnglish (US)
Pages (from-to)631-634
Number of pages4
JournalCancer Epidemiology Biomarkers and Prevention
Volume7
Issue number7
StatePublished - Jul 1 1998

ASJC Scopus subject areas

  • Epidemiology
  • Oncology

Fingerprint Dive into the research topics of 'Evaluation of biomarkers of survival response in hormone-refractory prostate cancer patients treated with suramin'. Together they form a unique fingerprint.

Cite this